Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: Results of AIDS Clinical Trials Group 5108 study

Journal of Acquired Immune Deficiency Syndromes

Volumn 39, Issue 3, 2005, Pages 307-312

  Gerber, John G ^a   Rosenkranz, Susan L ^b   Fichtenbaum, Carl J ^c   Vega, Jose M ^d   Yang, Amy ^d   Alston, Beverly L ^e   Brobst, Susan W ^f   Segal, Yoninah ^b   Aberg, Judith A ^g  

^a UNIVERSITY OF COLORADO   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^g WASHINGTON UNIVERSITY   (United States)

Author keywords

Drug interactions; HIV infection; Hydroxymethylglutaryl coenzyme A reductase inhibitors; Nonnucleoside reverse transcriptase inhibitors; Statins

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CREATINE KINASE; CYTOCHROME P450 3A4; EFAVIRENZ; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SIMVASTATIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPERLIPIDEMIA; INSOMNIA; MAJOR CLINICAL STUDY; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOSIS;

ADULT; ANTI-HIV AGENTS; CHOLESTEROL, LDL; DRUG INTERACTIONS; FEMALE; HEPTANOIC ACIDS; HIV INFECTIONS; HIV SERONEGATIVITY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; OXAZINES; PRAVASTATIN; PYRROLES; SIMVASTATIN;

EID: 21544472342     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000167156.44980.33     Document Type: Article

References (29)

1. Friis-Moller N, Sabin CA, Weber R, et al. Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group: combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003; 349:1993-2003.
2. Mauss S. HIV-associated and antiretroviral-induced hyperlipidaemia: an update. J HIV Ther. 2003;8:29-31.
3. Fontas E, van Leth F, Sabin CA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis. 2004;189:1056-1074.
4. Simon GL, Liappis AP, Granger SL, et al. Antiretroviral therapy-induced changes in lipoprotein subclass phenotype: comparison of protease inhibitor and non-nucleoside reverse transcriptase inhibitor regimens [abstract 14]. Antivir Ther. 2002;7:L9.
5. Tashima KT, Bausserman L, Alt EN, et al. Lipid changes in patients initiating efavirenz- and indinavir-based antiretroviral regimens. HIV Clin Trials. 2003;4:29-36.
6. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Clin Pharmacokinet. 1997;32:403-425.
7. Adkins JC, Noble S. Efavirenz. Drugs. 1998;56:1055-1064.
8. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. NIAID AIDS Clinical Trials Group. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS. 2002;16:569-577.
9. Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther. 1998;63:332-341.
10. Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Med. 1995;333: 664-665.
11. Hare CB, Vu MP, Grunfeld C, et al. Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death. Clin Infect Dis. 2002;35(Suppl): e111-e112.
12. Malhotra HS, Goa KL. Atorvastatin. An updated review of its pharmacological properties and use in dyslipidaemia. Drugs. 2001;61:1835-1881.
13. Everett DW, Chando TJ, Didonato GC, et al. Biotransformation of pravastatin sodium in humans. Drug Metab Dispos. 1991;19:740-748.
14. Hsyu PH, Schultz-Smith MD, Lillibridge JH, et al. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother. 2001;45:3445-3450.
15. Zhao JJ, Xie IH, Yang AY, et al. Quantitation of simvastatin and its beta-hydroxy acid in human plasma by liquid-liquid cartridge extraction and liquid chromatography-tandem mass spectrometry. J Mass Spectrom. 2000;35:1133-1143.
16. Rogers JD, Zhao J, Liu L, et al. Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Clin Pharmacol Ther. 1999;66:358-366.
17. Jemal M, Ouyang A, Chen B, et al. Quantitation of the acid and lactone forms of atorvastatin and its biotransformation products in human serum by high-performance liquid chromatography with electrospray tandem mass spectrometry. Rapid Commun Mass Spectrom. 1999;13:1003-1015.
18. Mulvana D, Jemal M, Coates-Pulver S. Quantitative determination of pravastatin and its biotransformation products in human serum by turbo ion spray LC/MS/MS. J Pharm Biomed Anal. 2000;23:851-866.
19. Turner ML, Reed-Walker K, King JR, et al. Simultaneous quantitation of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma using a single high-performance liquid chromatography methodology. J Chromatogr B Biomed Appl. 2003;784:331-341.
20. Hahn GJ, Meeker WQ. Statistical Intervals: A Guide for Practitioners. New York: John Wiley and Sons; 1991.
21. FDA Guidance for Industry. In Vivo Drug Metabolism/Drug Interaction Studies-Study Design, Data Analysis and Recommendations for Dosing and Labeling. US Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER); Rockville, MD. 1999.
22. FDA Guidance for Industry. Statistical Approaches to Establishing Bioequivalence. US Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); Rockville, MD. 2001.
23. Carr RA, Andre AK, Bertz RJ, et al. Concomitant administration of ABT-378/ritonavir (ABT-378/r) results in a clinically important pharmacokinetic (PK) interaction with atorvastatin (ATO) but not pravastatin (PRA) [abstract 1644]. Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000; Toronto.
24. Back D, Gibbons S, Khoo S. Pharmacokinetic drug interactions with nevirapine. J Acquir Immune Defic Syndr. 2003;34(Suppl 1):S8-S14.
25. Tran JQ, Gerber JG, Kerr BM. Delavirdine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2001;40:207-226.
26. Arnadottir M, Eriksson LO, Thysell H, et al. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor activity in kidney transplant recipients with and without ciclosporin. Nephron. 1993;65:410-413.
27. Yamazaki M, Akiyama S, Ni'inuma K, et al. Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 1997;25:1123-1129.
28. Nakai D, Nakagomi R, Furuta Y, et al. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Ther. 2001;297:861-867.
29. Mwinyi J, Johne A, Bauer S, et al. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther. 2004;75:415-421.